About Astonea Labs Limited

Business Overview

Astonea Labs specializes in the manufacturing and marketing of pharmaceutical and cosmetic products, including antibiotics, anti-cold medications, antihistamines, diabetes and cardiovascular drugs, gynecological treatments, analgesics, antifungals, and multivitamins. The cosmetic segment includes skin, tooth, and hair care products in forms such as gels, creams, lotions, oils, and serums—all compliant with pharmaceutical and cosmetic industry standards.

Headquartered in Haryana, India, the company operates a 7,500 sq. meter ISO-certified manufacturing facility. It is engaged in contract manufacturing for Indian and international clients, alongside marketing its own brands—"Glow Up" and "Regero"—in the domestic market. "Glow Up" products are also sold via Amazon and Tata 1MG. A new skincare range under the brand "Avicel" is set to launch soon.

Astonea Labs also deals in the trading of packing and raw materials used in pharmaceuticals and cosmetics. On the global front, products are exported to Iraq and Yemen, and following a recent USFDA audit for OTC products, the company is strategically positioned to enter the U.S. and other international markets. As of December 31, 2024, the Company have 217 employees on payroll and they also engage contractual labour as per operational requirements resulting in fluctuation in the number of contract labour. The Banker to the Company is Small Industries Development Bank of India, HDFC Bank Ltd and IDFC First Bank.

Industry Analysis

India's Global Pharma Leadership

India has cemented its position as a global powerhouse in pharmaceuticals. Known for its affordable generic drugs and vaccines, the Indian pharmaceutical industry ranks third globally in volume and 14th in value, reflecting both scale and impact.

With a CAGR of 9.43% over the past nine years, the sector encompasses segments like generic drugs, biosimilars, contract manufacturing, biologics, and over-the-counter medicines. Over 50% of global vaccine demand, 40% of generic drugs in the U.S., and 25% of UK’s medicine are supplied by India. The country boasts 3,000 drug companies and 10,500 manufacturing units, with 500 API producers covering 8% of the global API market.

Notably, India houses the highest number of USFDA-compliant plants outside the U.S., giving it a competitive edge in regulated markets.

Export Performance and Global Reach

India exported $27.9 billion worth of drugs and pharmaceuticals in FY24, serving over 200 countries. The United States remains the largest export destination, followed by Western Europe, Japan, and Australia. About 20% of the global generic export volume originates from India.

India supplied 45 tonnes and 400 million tablets of hydroxychloroquine to 114 nations during the pandemic. It also distributed 301 million doses of COVID-19 vaccines to over 100 countries, showcasing its capability and international goodwill.

Market Size and Growth Trajectory

• Current Valuation (2023–24): ~$50 billion (with over $25 billion from exports)

• 2024 Target: $65 billion

• 2030 Target: ~$130 billion

• 2047 Projection: ~$450 billion

According to CRISIL, domestic sales are expected to grow by 8–10% in FY24, while ICRA estimates a 9–11% growth rate in the same period.

Medical Devices & Biotechnology Sectors

India’s medical devices market, valued at $10.36 billion in FY20, is expected to skyrocket to $50 billion by 2025 at a CAGR of 37%. The biotechnology industry—comprising biopharma, bio-agriculture, and bioinformatics—was valued at $137 billion in 2022, with a goal to reach $300 billion by 2030.

Government Support and Future Outlook

The Indian government is focusing on:

• National Health Protection Scheme

• Rural healthcare initiatives

• Inexpensive generic medicine outlets

• Promoting lifesaving drugs and chronic disease therapies like anti-diabetes, anti-depressants, and oncology medications

Medicine spending in India is projected to grow 9–12% over five years, placing it among the top 10 global markets.

Evolution of the Indian Cosmetic Industry

India’s cosmetic industry is undergoing phenomenal growth, driven by:

• Rising disposable income

• Youth population embracing global beauty standards

• Increased awareness due to digital media and e-commerce

From $11.6 billion in 2017, the industry is expected to reach $20 billion by 2025, with a CAGR of 15–20%. Both organized (44%) and unorganized (55%) sectors are contributing significantly.

Future of Beauty and Skincare in India

The sector now spans:

• Cosmetics and personal care

• Beauty appliances

• Wellness services

Consumers are increasingly shifting toward self-care and preventive skincare routines, reducing dependence on traditional medical treatments.

With the booming demand, numerous new entrants are bringing innovative products and ingredients, supported by digital channels and influencer marketing.

Conclusion

India’s pharmaceutical and cosmetic sectors are not only pillars of the domestic economy but also vital players in the global supply chain. With ongoing investments, government initiatives, and export strength, both industries are poised for exponential growth through 2030 and beyond

Business Strengths

1. Experienced Management & Skilled Workforce
Led by a management team with over 6 years of industry experience, Astonea Labs has established a sustainable business model through strong supplier and customer relationships. The company employs technically qualified professionals and follows strategies to recruit and retain skilled employees, emphasizing the vital role of human resources in organizational success.

2. Scalable Business Model
Astonea Labs operates a customer-centric and order-driven model, optimized for resource efficiency and quality assurance. Growth is driven by market expansion and new product development across domestic and international markets, achieving economies of scale through consistent quality and strategic marketing.

3. Diverse Product Portfolio
The company offers a broad range of pharmaceutical and cosmetic products, including antibiotics, antihistamines, anti-cold, diabetes and cardiovascular drugs, gynecological treatments, analgesics, antifungals, multivitamins, and skin and hair care solutions. Products are available in various forms like tablets, capsules, gels, creams, lotions, oils, and serums, all meeting strict industry standards.

4. Commitment to Quality Service
Astonea Labs emphasizes timely and high-quality service, backed by stringent systems to ensure on-time delivery and minimal product rejections. This focus has fostered customer loyalty, retention, and repeated orders, contributing to the continuous expansion of its customer base

Business Strategies

1. Expansion of Product Portfolio
Introducing new product ranges to optimize manufacturing capacity, manpower, and resources, supported by an established customer base, strong trade relations, and industry goodwill.

2. Strengthening Existing Offerings
Enhancing market penetration and reach within the current product portfolio by leveraging market insights, deepening customer relationships, and identifying innovation and differentiation opportunities.

3. Export Division Growth
Focusing on global market expansion through regulatory compliance, manufacturing expertise, and quality assurance. Emphasis on efficient logistics, timely delivery, and market-specific solutions to build strong international customer relationships.

4. Targeting New and Regulated Markets
Strategic entry into unexplored and regulated markets, with tailored growth strategies aligned to local regulations. Growth to be driven by commercialization of registered products, market evaluations, and potential acquisitions or strategic partnerships.

5. Leveraging Marketing Capabilities
Continuous focus on enhancing client satisfaction by utilizing strong marketing skills and industry relationships, ensuring effective customer engagement and sustained business development

Business Risk Factors and Concerns

1. Non-Compliance with FDA’s OTC Monograph User Fee Program
Failure to meet the annual obligation under the OTC Monograph User Fee Program has resulted in all OTC monograph products being classified as misbranded under Section 502(ff) of the FD&C Act. This prohibits their legal sale in interstate commerce and places the company on the FDA’s arrears list, which may harm reputation and business operations until compliance is restored.

2. High Dependency on Third-Party Suppliers
A significant proportion of raw materials, such as glycerin, menthol, niacinamide, paracetamol, azithromycin, and others, are sourced from third-party suppliers. Between 33.90% and 55.74% of total purchases in recent fiscal years were from the top 10 suppliers. Any failure on the part of these suppliers could disrupt production and adversely affect operational continuity.

3. Concentration in Pharmaceutical Segment
A major share of revenue is derived from the pharmaceutical segment. This exposes the company to risks from regulatory shifts, market volatility, healthcare policy changes, and competitive disruptions. Such factors may lead to revenue loss or increased operational challenges.

4. Reliance on Contract Manufacturing
The primary business model depends on contract manufacturing for third-party clients. Any decline in outsourcing demand, client attrition, or pricing pressures could materially affect revenue and profitability.

5. Exposure to Regulatory Risks
Operating in the pharmaceutical and cosmetic sectors involves compliance with stringent regulatory norms across multiple jurisdictions. Non-compliance may lead to litigation, financial penalties, or damage to reputation. Despite adherence to SOPs, quality standards, and internal audits, the company remains vulnerable to regulatory changes and audit findings in both regulated and semi-regulated markets.

Astonea Labs faces several operational, regulatory, and dependency-related risks that could materially impact its financial performance, including non-compliance with FDA user fee requirements, supplier dependency, industry concentration, regulatory exposure, and overreliance on contract manufacturing and the pharmaceutical segment.